Pancreatic cancer; Pathogenic mutation of the BRCA1 gene

Abstract

Pancreatic cancer, although rare, ranks seventh in terms of cancer-related mortality, with a low five-year survival rate after diagnosis. Globally, it accounts for approximately 1.6-1.2% of cancer cases. In Mexico, it is also a significant cause of mortality, ranking sixth or seventh. This type of cancer tends to occur more frequently in individuals over the age of 71, but there has been a marked increase in its incidence among younger patients. One of the most common risk factors is a family history of the disease, and a close relationship has often been noted between pancreatic cancer and newly diagnosed diabetes mellitus. The primary objective of this study is to understand pancreatic cancer prevention in patients carrying the pathogenic mutation of the BRCA1 gene and explore innovative therapies. Both the BRCA1 and BRCA2 genes have been associated with various cancer types, such as breast, ovarian, and pancreatic cancer. In the case of the latter, it is believed that these genes may contribute to cancer by causing DNA damage. The diagnosis of pancreatic cancer is based on imaging studies and biopsies. Furthermore, various treatment options are examined, including neoadjuvant therapies and potential therapeutic approaches.